Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3348_Библиотеки_им_академика_М_И_Перельмана
.pdf
121
98) Karg MV, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-
Zelch F, Linz P, Nagel AM, Titze J, Uder M, Schmieder RE. SGLT-2-inhibition
with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Cardiovasc Diabetol. 2018 Jan 4;17(1):5.
99) Nassif, M.E., Windsor, S.L., Borlaug, B.A. et al. The SGLT2 inhibitor
dapagliflozin in heart failure with preserved ejection fraction: a multicenter
randomized trial. Nat Med 27, 1954–1960 (2021).
100) Nassif ME, Windsor SL, Gosch K, Borlaug BA, Husain M, Inzucchi SE,
Kitzman DW, McGuire DK, Pitt B, Scirica BM, Shah SJ, Umpierrez G, Austin
BA, Lamba S, Khumri T, Sharma K, Kosiborod MN. Dapagliflozin Improves
Heart Failure Symptoms and Physical Limitations Across the Full Range of
Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and
PRESERVED-HF Trials. Circ Heart Fail. 2023 Jul;16(7):e009837.
101) Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A,
Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert
RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA. Effect of
Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes
Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6
Randomized Clinical Trial. Circulation. 2019 Nov 19;140(21):1693-1702.
102) Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero
A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F,
Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP,
Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V,
Badimon JJ; EMPA-TROPISM (ATRU-4) Investigators. Randomized Trial of
Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection
Fraction. J Am Coll Cardiol. 2021 Jan 26;77(3):243-255.
103) Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an
Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors
(DISCOVERSGLT2i) ClinicalTrials.gov: NCT05344963
122
104) Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, Lamba S,
Bhatt K, Brush J, Civitello A, Gordon R, Jonsson O, Lampert B, Pelzel J,
Kosiborod MN. Empagliflozin Effects on Pulmonary Artery Pressure in Patients
With Heart Failure: Results From the EMBRACE-HF Trial. Circulation. 2021
Apr 27;143(17):1673-1686.
105) Cogliati C, Casazza G, Ceriani E, Torzillo D, Furlotti S, Bossi I, Vago T,
Costantino G, Montano N. Lung ultrasound and short-term prognosis in heart
failure patients. Int J Cardiol. 2016 Sep 1;218:104-108.
106) Rivas-Lasarte M, Álvarez-García J, Fernández-Martínez J, Maestro A, López-
López L, Solé-González E, Pirla MJ, Mesado N, Mirabet S, Fluvià P, Brossa V,
Sionis A, Roig E, Cinca J. Lung ultrasound-guided treatment in ambulatory
patients with heart failure: a randomized controlled clinical trial (LUS-HF
study). Eur J Heart Fail. 2019 Dec;21(12):1605-1613.
107) Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M,
Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E,
Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod
MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM,
Sjöstrand M, McMurray JJV. Efficacy of Dapagliflozin on Renal Function and
Outcomes in Patients With Heart Failure With Reduced Ejection Fraction:
Results of DAPA-HF. Circulation. 2021 Jan 26;143(4):298-309.
108) Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the
continuing saga. Diabetes Care. 2014;37(3):867-75.
109) Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and
clinical prospects. Nat Rev Endocrinol. 2012 Feb 7;8(8):495-502.
110) Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan
NM, Woerle HJ, Johansen OE, Broedl UC, Eynatten M. The Renal
Hemodynamic Effect of SGLT2 Inhibition in Patients with Type 1 Diabetes.
Circulation. 2014;129:587–597.
123
111) Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors
in the management of type 2 diabetes. Diabetes Metab Syndr Obes. 2012;5:313–
327.
112) Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus
M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG
OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and
Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.
113) Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC;
EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin
added to existing antidiabetes treatment in patients with type 2 diabetes and
chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol. 2014 May;2(5):369-84.
114) Readily Available Urinary Sodium Analysis in Patients With Acute
Decompensated Heart Failure (EASY-HF) ClinicalTrials.gov: NCT06278792.
https://esc365.escardio.org/presentation/287328
115) Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of
glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017
Jan;19(1):43-53.
116) Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron
Clin Pract. 2012;120(4):c179-84.
117) Joannidis M, Metnitz B, Bauer P, Schusterschitz N, Moreno R, Druml W,
Metnitz PG. Acute kidney injury in critically ill patients classified by AKIN
versus RIFLE using the SAPS 3 database. Intensive Care Med. 2009
Oct;35(10):1692-702.
118) Xiong J, Tang X, Hu Z, Nie L, Wang Y, Zhao J. The RIFLE versus AKIN
classification for incidence and mortality of acute kidney injury in critical ill
patients: A meta-analysis. Sci Rep. 2015 Dec 7;5:17917.
119) EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C,
Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA,
Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK,
124
Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D,
Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D,
Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C,
Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J
Med. 2023 Jan 12;388(2):117-127.
120) Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou
FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD,
Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators.
Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct
8;383(15):1436-1446.
121) Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, Gustafsson F,
Faber J, Malik ME, Fosbøl EL, Bruun NE, Forman JL, Jensen LT, Møller JE,
Schou M. Effects of empagliflozin on estimated extracellular volume, estimated
plasma volume, and measured glomerular filtration rate in patients with heart
failure (Empire HF Renal): a prespecified substudy of a double-blind,
randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2021
Feb;9(2):106-116.
Соседние файлы в папке Библиотека им академика М.И. Перельмана